Cargando…

Outcomes of asymptomatic recombinant tissue plasminogen activator associated intracranial hemorrhage

BACKGROUND: Intracranial hemorrhage (ICH) is the most devastating complication of recombinant tissue plasminogen activator (rtPA) treatment in acute ischemic stroke patients. Data on rtPA-associated asymptomatic ICH (aICH) are limited. OBJECTIVES: To determine the incidence, risk factors, characteri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teekaput, Chutithep, Thiankhaw, Kitti, Tanprawate, Surat, Teekaput, Kanokkarn, Chai-Adisaksopha, Chatree
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342748/ https://www.ncbi.nlm.nih.gov/pubmed/35913922 http://dx.doi.org/10.1371/journal.pone.0272257

Ejemplares similares

Cerebral venous sinus thrombosis in immune thrombocytopenia patients treated with thrombopoietin receptor agonist: Case reports and literature review
por: Teekaput, Chutithep, et al.
Publicado: (2022)

Preseptal and Pretarsal Botulinum Toxin Injection in Hemifacial Spasm and Blepharospasm: A 10-Year Comparative Study
por: Teekaput, Chutithep, et al.
Publicado: (2023)

Serum NT-proBNP level for predicting functional outcomes after acute ischemic stroke
por: Srisujikul, Phattheera, et al.
Publicado: (2023)

A Simplified Risk Score to Predict In-Hospital Newly-Diagnosed Atrial Fibrillation in Acute Ischemic Stroke Patients
por: Saengmanee, Thanachporn, et al.
Publicado: (2023)

Cryptococcal Meningitis: Differences between Patients with and without HIV-Infection
por: Teekaput, Chutithep, et al.
Publicado: (2023)

Implications of the Presence of Hyperdense Middle Cerebral Artery Sign in Determining the Subtypes of Stroke Etiology
por: Sangpetch, Suchada, et al.
Publicado: (2021)

Recombinant tissue plasminogen activator in the treatment of suprachoroidal hemorrhage
por: Kunjukunju, Nancy, et al.
Publicado: (2011)

Tissue Plasminogen Activator Induced Delayed Edema in Experimental Porcine Intracranial Hemorrhage: Reduction with Plasminogen Activator Inhibitor-1 Administration
por: Keric, Naureen, et al.
Publicado: (2012)

Characteristics of blood tests in patients with acute cerebral infarction who developed symptomatic intracranial hemorrhage after intravenous administration of recombinant tissue plasminogen activator
por: Lee, Chungjo, et al.
Publicado: (2019)

Predictors of Intracerebral Hemorrhage in Acute Stroke Patients Receiving Intravenous Recombinant Tissue Plasminogen Activator
por: Chenna, Vijay, et al.
Publicado: (2018)

Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals
por: Matino, Davide, et al.
Publicado: (2017)

Internal carotid artery and bilateral vertebral arteries dissections associated with amphetamine abuse: Case report
por: Sirimaharaj, Nopdanai, et al.
Publicado: (2021)

Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator
por: Ong, Cheung-Ter, et al.
Publicado: (2017)

Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study
por: Manosroi, Worapaka, et al.
Publicado: (2022)

306. Development a Predictive Score for Severe Coronavirus Disease 2019 (COVID-19) from High Risk Factor of Patient Described by Thai Government Policy
por: Noopetch, Preudtipong, et al.
Publicado: (2022)

Clinicopathological study and outcomes of primary extranodal lymphoma
por: Nanthakwang, Nichapa, et al.
Publicado: (2019)

Serum Creatinine May Indicate Risk of Symptomatic Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator (IV tPA)
por: Marsh, Elisabeth B., et al.
Publicado: (2013)

Tissue Plasminogen Activator Toxicity after Submacular Hemorrhage Repair
por: Islam, Yasmin, et al.
Publicado: (2021)

Enzymatic vitreolysis with recombinant tissue plasminogen activator for vitreomacular traction
por: Raczyńska, Dorota, et al.
Publicado: (2015)

Tissue Plasminogen Activator Neurotoxicity is Neutralized by Recombinant ADAMTS 13
por: Fan, Mengchen, et al.
Publicado: (2016)

A Canine Model of Hemorrhagic Transformation Using Recombinant Tissue Plasminogen Activator Administration After Acute Ischemic Stroke
por: Jiang, Run-Hao, et al.
Publicado: (2019)

Impact of type of anticoagulant on clinical outcomes in cancer patients who had atrial fibrillation
por: Chai-Adisaksopha, Chatree, et al.
Publicado: (2023)

Conglomerate ring and tract-like enhancement lesions: Neuroimaging in Listeria monocytogenes brain abscess
por: Thiankhaw, Kitti, et al.
Publicado: (2021)

Outcomes of Non-Cryopreserved Versus Cryopreserved Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Piriyakhuntorn, Pokpong, et al.
Publicado: (2020)

A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature
por: Chai-Adisaksopha, Chatree, et al.
Publicado: (2016)

Developing diagnostic criteria to differentiate fungal foot infections caused by Neoscytalidium dimidiatum and dermatophytes
por: Leeyaphan, Charussri, et al.
Publicado: (2023)

Functional Outcome Measures of Recombinant Tissue Plasminogen Activator–Treated Stroke Patients in the Telestroke Technology
por: Gainey, Jordan, et al.
Publicado: (2018)

Tissue Plasminogen Activator-Assisted Vitrectomy for Ruptured Eye with Suprachoroidal Hemorrhage
por: Matsumoto, Koichi, et al.
Publicado: (2012)

Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients
por: Gurbuz, Yunus, et al.
Publicado: (2015)

Combined Administration of Preoperative Intravitreal and Intraoperative Subretinal Recombinant Tissue Plasminogen Activator in Acute Hemorrhagic Age-related Macular Degeneration
por: Helaiwa, Khaled, et al.
Publicado: (2020)

Long-term stability of recombinant tissue plasminogen activator at -80 C
por: Shaw, George J, et al.
Publicado: (2009)

Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis
por: Yang, Hung-Wei, et al.
Publicado: (2012)

Pharmacokinetics and thrombolytic effects of the recombinant tissue-type plasminogen activator in horses
por: Bäumer, Wolfgang, et al.
Publicado: (2013)

Intrapericardial recombinant tissue plasminogen activator in purulent pericarditis- case series
por: Dybowska, Małgorzata, et al.
Publicado: (2020)

The diagnostic tests and functional outcomes of acute ischemic stroke or transient ischemic attack in young adults: A 4-year hospital-based observational study
por: Sakseranee, Jakraphat, et al.
Publicado: (2023)

Risk Factors Associated with Outcomes of Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Ischemic Stroke
por: Tseng, Yi-Ju, et al.
Publicado: (2020)

Subretinal recombinant tissue plasminogen activator and pneumatic displacement for the management of subretinal hemorrhage occurring after anti-VEGF injections for wet AMD
por: Tognetto, Daniele, et al.
Publicado: (2011)

Differences between predictive factors for early neurological deterioration due to hemorrhagic and ischemic insults following intravenous recombinant tissue plasminogen activator
por: Tanaka, Koji, et al.
Publicado: (2019)

Three-dimensional heads-up system assisted pars plana vitrectomy and subretinal recombinant tissue plasminogen activator injection for submacular hemorrhage
por: Zhao, Xinyu, et al.
Publicado: (2023)

Factors Associated with Unfavorable Functional Outcomes After Intravenous Thrombolysis in Patients with Acute Ischemic Stroke
por: Satumanatpan, Nat, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kqpd7p9tft99clgagmi34b5s3k